PMID- 9643569
OWN - NLM
STAT- MEDLINE
DCOM- 19980929
LR  - 20190116
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 29
IP  - 5-6
DP  - 1998 May
TI  - Minimal residual disease in acute myelogenous leukemia with PML/RAR alpha or 
      AML1/ETO mRNA and phenotypic analysis of possible T and natural killer cells in 
      bone marrow.
PG  - 553-61
AB  - Here we studied minimal residual disease (MRD) of patients with acute myeloid 
      leukemia (AML) who have PML/RAR alpha or AML1/ETO as well as the phenotypic 
      analysis of lymphocyte subsets involved in antitumor immunity. Eight patients in 
      long-term (LT; 3 to 15 years) and 15 patients in short-term (ST; up to 3 years) 
      remission were studied. Using the reverse transcription-polymerase chain reaction 
      (RT) assay, the limit of detection was 10(-5) to 10(-6) for PML/RAR alpha 
      transcript and 10(-4) to 10(-5) for the AML1/ETO transcript. Simultaneously, T 
      lymphocyte subsets and NK cells from the peripheral blood (PB) and bone marrow 
      (BM) were investigated by flow cytometric analysis. Four of the eight patients in 
      LT and 7 of the 15 patients in ST remission were MRD-positive. Although all 
      MRD-positive patients in LT remission are still until now event-free, 3 of the 7 
      MRD-positive (MRD+) patients in ST remission soon relapsed. The total populations 
      of CD4+, CD8+ and CD56+ [possible T-cell and natural killer (T/NK) populations] 
      in the BM of ST patients and MRD+/LT patients were significantly (p < .01) low. 
      The CD8+ CD28+ population showed the same tendency (p < .01-.02). The T/NK 
      subsets in the BM of MRD-negative (MRD-) LT (MRD-/LT) patients showed similar 
      numbers of cells as normal volunteers. Basically, the total percentage of the 
      CD4+, CD8+ and CD56+ cell populations in the BM was increased and in the 
      following order: MRD-/LT patients, normal volunteers, MRD+/LT patients and MRD+ 
      or -/ST patients. The percentages of the T/NK-cell subsets in the PB were not 
      significantly different among these groups. Thus, the difference of the possible 
      T/NK-cell phenotype in the BM may strongly influence clinical and molecular 
      remission. These results still remain to be confirmed by further studies of the 
      functional anti-tumor immunity of T/NK cells of AML in remission.
FAU - Inokuchi, K
AU  - Inokuchi K
AD  - Division of Hematology, Department of Internal Medicine, Nippon Medical School, 
      Tokyo, Japan.
FAU - Iwakiri, R
AU  - Iwakiri R
FAU - Futaki, M
AU  - Futaki M
FAU - Hanawa, H
AU  - Hanawa H
FAU - Tanosaki, S
AU  - Tanosaki S
FAU - Nomura, T
AU  - Nomura T
FAU - Dan, K
AU  - Dan K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (AML1-ETO fusion protein, human)
RN  - 0 (Core Binding Factor Alpha 2 Subunit)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (RUNX1 Translocation Partner 1 Protein)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Transcription Factors)
RN  - 0 (promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein)
SB  - IM
MH  - Core Binding Factor Alpha 2 Subunit
MH  - DNA, Neoplasm/analysis
MH  - Disease-Free Survival
MH  - Flow Cytometry
MH  - Humans
MH  - Immunophenotyping
MH  - Killer Cells, Natural/*pathology
MH  - Leukemia, Myeloid, Acute/genetics/mortality/*pathology
MH  - Leukemia, Promyelocytic, Acute/genetics/mortality/*pathology
MH  - Neoplasm Proteins/*analysis/genetics
MH  - Neoplasm, Residual
MH  - Oncogene Proteins, Fusion/*analysis/genetics
MH  - Polymerase Chain Reaction
MH  - Predictive Value of Tests
MH  - RUNX1 Translocation Partner 1 Protein
MH  - Recombinant Fusion Proteins/analysis/genetics
MH  - Remission Induction
MH  - T-Lymphocyte Subsets/*pathology
MH  - Time Factors
MH  - Transcription Factors/*analysis/genetics
EDAT- 1998/06/27 00:00
MHDA- 1998/06/27 00:01
CRDT- 1998/06/27 00:00
PHST- 1998/06/27 00:00 [pubmed]
PHST- 1998/06/27 00:01 [medline]
PHST- 1998/06/27 00:00 [entrez]
AID - 10.3109/10428199809050915 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 1998 May;29(5-6):553-61. doi: 10.3109/10428199809050915.